Haleon PLC (HLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rashad Kawan from Morgan Stanley upgraded the rating on the stock to a Buy and gave it a p425.00 price target.
Rashad Kawan has given his Buy rating due to a combination of factors that highlight Haleon PLC’s potential for outperformance in the current uncertain economic environment. The company operates in resilient categories and is expected to gain market share, supported by a well-defined cost-saving program that promises continued success relative to its peers.
Additionally, Haleon’s strategic initiatives, including an £800 million cost-saving plan, provide greater visibility into margin expansion from 2026 onwards. The company’s exposure to defensive categories makes it an attractive investment, especially given the macroeconomic uncertainties. Kawan anticipates a higher EPS growth rate from 2026 to 2030, positioning Haleon ahead of its household and personal care peers, which justifies the upgrade to a Buy rating.
In another report released on May 6, Citi also maintained a Buy rating on the stock with a £4.55 price target.